| - |
Sofosbuvir/Velpatasvir |
Epclusa® |
For the treatment of chronic hepatitis C virus (HCV) infection in adults |
Rapid review complete |
23rd August 2016 |
 |
| - |
Sofosbuvir/velpatasvir |
Epclusa® |
For the treatment of chronic hepatitis C virus (HCV) infection in adults. This indication covers all genotypes (GT1, 2, 3, 4, 5 and 6) i.e. pangenotypic. |
Rapid review complete |
19th October 2017 |
|
| - |
Sofosbuvir/Velpatasvir/Voxilaprevir |
Vosevi® |
For the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic i.e. all genotypes (GT1, 2, 3, 4, 5 and 6). |
Rapid review complete |
15th November 2017 |
|
| 22017 |
Solriamfetol |
Sunosi® |
To improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy). |
Rapid review complete |
11th April 2022 |
|
| 23060 |
Somapacitan |
Sogroya® |
Somapacitan (Sogroya®) is indicated for the replacement of endogenous growth hormone in children aged three years and above and adolescents with growth failure due to growth hormone deficiency (GHD), and in adults with GHD. |
Rapid Review Complete |
27th November 2023 |
|
| 22010 |
Somatrogon |
Ngenla® |
For the treatment of children and adolescents from three years of age with growth disturbance due to insufficient secretion of growth hormone |
Rapid review complete |
25th March 2022 |
|
| 24041 |
Sotatercept |
Winrevair ® |
Sotatercept, in combination with other pulmonary arterial hypertension (PAH) therapies, is indicated for the treatment of PAH in adult patients with WHO Functional Class II to III, to improve exercise capacity. |
Rapid Review Complete |
24th October 2024 |
|
| 21070 |
Sotorasib |
Lumykras® |
As monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy. |
Rapid review complete |
25th January 2022 |
|
| 24020 |
Sparsentan |
Filspari® |
For the treatment of adults with primary immunoglobulin A (IgA) nephropathy with a urine protein excretion >1.0 g/day (or urine protein-to-creatine ratio ≥0.75 g/g). |
Awaiting full HTA submission from Applicant |
1st October 2024 |
|
| - |
St Johns Wort |
Pacifa® |
For the short term treatment of mild depressive symptoms. |
Rapid review complete |
29th May 2015 |
|
| - |
Stiripentol |
Diacomit® |
In conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and valproate |
Assessment process complete |
3rd May 2019 |
|
| - |
Sublingual Immunotherapy |
Grazax® |
For the Prevention of Seasonal Grass Pollen-Induced Rhinoconjunctivitis. |
Rapid review complete |
4th September 2007 |
|
| - |
Sufentanil |
Zalviso® |
For the management of acute moderate to severe post-operative pain in adult patients. |
Assessment process complete |
22nd March 2016 |
|
| __ |
Sufentanil Citrate |
Dzuveo® |
For the management of acute moderate to severe pain in adult patients |
Rapid Review Complete |
22nd December 2023 |
|
| - |
Sunitinib |
Sutent® |
As second-line treatment of patients with gastro-intestinal stromal tumours (GIST); As second line treatment for patients with metastatic renal cell carcinoma (mRCC) |
Assessment process complete |
9th November 2006 |
|
| - |
Tadalafil |
Adcirca® |
In adults for the treatment of pulmonary arterial hypertension (PAH) classified as World Health Organisation (WHO) Functional Class (FC) II and III, to improve exercise capacity. |
Rapid Review Complete |
27th May 2014 |
|
| 20017 |
Tafamidis |
Vyndaqel® |
For the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy. |
Assessment process complete |
25th September 2020 |
|
| - |
Tafamidis meglumine |
Vyndaqel® |
For the treatment of transthyretin amyloidosis in adult patients with stage I symptomatic polyneuropathy to delay peripheral neurologic impairment. |
Rapid Review Complete |
10th May 2018 |
|
| 22008 |
Tafasitamab |
Minjuvi® |
In combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem-cell transplant (ASCT). |
Rapid Review Complete |
15th February 2022 |
|
| - |
Tafluprost |
Saflutan® |
For the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension. |
Rapid Review Complete |
9th April 2011 |
|
| 19032 |
Talazoparib |
Talzenna® |
As monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. |
Assessment process complete |
18th September 2020 |
|
| 23074 |
Talazoparib |
Talzenna® |
Talazoparib (Talzenna®) in combination with enzalutamide is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. |
Rapid Review Complete |
21st December 2023 |
|
| - |
Talimogene laherparepvec |
Imlygic® |
For the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. |
Rapid Review Complete |
15th March 2016 |
|
| 23057 |
Talquetamab |
Talvey® |
Talquetamab is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
Full HTA submission received from Applicant |
2nd May 2024 |
|
| - |
Tapentadol |
Palexia® |
For the management of adult patients with severe chronic/acute pain. |
Assessment process complete |
13th April 2011 |
|
| 23064 |
Tebentafusp |
Kimmtrak® |
Tebentafusp is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. |
Rapid Review Complete |
13th November 2023 |
|
| 22064 |
Teclistamab |
Tecvayli® |
As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
NCPE Assessment Process Complete |
4th July 2024 |
|
| - |
Tedizolid phosphate |
Sivextro® |
For the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults |
Rapid Review Complete |
7th July 2015 |
|
| - |
Teduglutide |
Revestive® |
For the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation. |
Assessment process complete |
16th March 2018 |
|
| __ |
Tegafur/Gimeracil/Oteracil |
Teysuno® |
For the treatment of advanced gastric cancer. |
Rapid Review Complete |
31st March 2012 |
|
| - |
Telaprevir |
Incivo® |
As add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1. |
Assessment process complete |
19th January 2012 |
|
| __ |
Telavancin |
Vibativ® |
For the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA). Vabitiv® should be used only in situations where it is known or suspected that other alternatives are not suitable. |
Rapid Review Complete |
13th January 2015 |
|
| 24046 |
Tenecteplase |
Metalyse® |
Tenecteplase (Metalyse®) is indicated in adults for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage. |
Rapid Review Complete |
27th November 2024 |
|
| 22025 |
Tepotinib |
Tepmetko® |
For the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. |
NCPE Assessment Process Complete |
29th November 2023 |
|
| - |
Teriflunomide |
Aubagio® |
For the first line treatment of adult patients with relapsing remitting multiple sclerosis (MS). |
Assessment process complete |
19th June 2014 |
|
| 23025 |
Tezepelumab |
Tezspire® |
Tezepelumab (Tezspire®) is indicated as add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma, who are inadequately controlled despite high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. |
Full HTA submission received from Applicant |
4th June 2024 |
|
| - |
Ticagrelor |
Brilique® |
For the prevention of atherothrombotic events in adult patients with Acute Coronary Syndrome (ACS) including patients managed medically, and those who are managed with PCI (Percutaneous Coronary Intervention) or CABG (Coronary Artery Bypass Graft). |
Assessment process complete |
11th October 2011 |
|
| - |
Ticagrelor |
Brilique® |
Co-administered with acetylsalicylic acid (ASA), for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event. |
Rapid Review Complete |
5th May 2016 |
|
| 19029 |
Tildrakizumab |
Ilumetri® |
For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
Assessment process complete |
25th November 2021 |
|
| 21054 |
Tirbanibulin |
Klisyri® |
For the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. |
Rapid Review Complete |
30th November 2021 |
|
| 24003 |
Tirzepatide |
Mounjaro® |
Tirzepatide (Mounjaro®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes. |
Pre submission consultation scheduled |
6th February 2024 |
|
| 24024 |
Tirzepatide |
(Mounjaro®) |
For chronic weight management, including weight loss and weight maintenance, in adults with an initial body mass index of: ≥30 kg/m2, or ≥27 kg/m2 to <30 kg/m2 in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus). |
Awaiting full HTA submission from Applicant |
15th October 2024 |
|
| - |
Tisagenlecleucel |
Kymriah® |
For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. |
Assessment process complete |
20th September 2019 |
|
| - |
Tisagenlecleucel |
Kymriah® |
For the treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse. |
Assessment process complete |
27th August 2019 |
|
| 22044 |
Tisagenlecleucel |
Kymriah® |
For the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. |
NCPE Assessment Process Complete |
12th August 2024 |
|
| - |
Tivozanib |
Fotivda® |
For the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. |
Rapid Review Complete |
24th January 2019 |
|
| 22015 |
Tixagevimab /cilgavimab |
Evusheld® |
For the pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg. |
NCPE Assessment Process Complete |
22nd December 2022 |
|
| 22074 |
Tixagevimab/cilgavimab |
Evusheld® |
Is indicated for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. |
Rapid Review Complete |
25th January 2023 |
|
| - |
Tobramycin |
TOBI Podhaler® |
For the suppressive therapy of chronic pulmonary infection due to Ps aeruginosa in adults and children aged 6 years and older with CF. |
Rapid Review Complete |
29th November 2010 |
|
| - |
Tocilizumab SC |
RoActemra® |
For the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate. |
Rapid Review Complete |
16th July 2014 |
|
